Administration of a TGFβRI kinase inhibitor augmented the immunogenicity and anti-tumor efficacy of adenoviral vector-based vaccines in multiple murine lung tumor models, promoting increased tumor infiltration of macrophages, NK cells and CD8+ T cells [138]. Here, CD8A is linked to neoplasm.